ResearcherAnhui University of Science and TechnologyActive in the last 2 years
Xia-Qing Li
Matched on ORCID iD 0000-0002-7748-7967; OpenAlex author ID A5063860382. Sources: OpenAlex.
Their work
- Papers
- 4 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2024: 1 paper · 2025: 3 papers
Papers 4
- ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α signaling. Co-author DOI 10.1016/j.tranon.2024.102261↗
- B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. Co-author DOI 10.1136/jitc-2024-010908↗
- OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-I. First author DOI 10.7150/thno.103494↗
- Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarcinoma. Co-author DOI 10.1186/s12885-024-11885-8↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Aziguli Tulamaiti · 4 shared papers, 2024–2025 · strength 0.85
- Paper B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. DOI 10.1136/jitc-2024-010908↗
- Paper OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-… DOI 10.7150/thno.103494↗
- Paper Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarci… DOI 10.1186/s12885-024-11885-8↗
- Xin Xing · 3 shared papers, 2024–2025 · strength 0.64
- Paper B4GALT5 inhibits CD8+ T-cell response by downregulating MHC-I level through ERAD pathway in PDAC. DOI 10.1136/jitc-2024-010908↗
- Paper OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-… DOI 10.7150/thno.103494↗
- Paper Identification of a novel m6A-related lncRNAs signature and immunotherapeutic drug sensitivity in pancreatic adenocarci… DOI 10.1186/s12885-024-11885-8↗
- Zhigang Zhang · 2 shared papers, 2025 · strength 0.44
- Dong‐Xue Li · 2 shared papers, 2025 · strength 0.43
- Paper OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-… DOI 10.7150/thno.103494↗
- Paper ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α … DOI 10.1016/j.tranon.2024.102261↗
- Xueli Zhang · 2 shared papers, 2025 · strength 0.43
- Li-Peng Hu · 2 shared papers, 2025 · strength 0.43
- Paper OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-… DOI 10.7150/thno.103494↗
- Paper ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α … DOI 10.1016/j.tranon.2024.102261↗
- Shu‐Heng Jiang · 2 shared papers, 2025 · strength 0.43
- Paper OASL promotes immune evasion in pancreatic ductal adenocarcinoma by enhancing autolysosome-mediated degradation of MHC-… DOI 10.7150/thno.103494↗
- Paper ENO1 promotes PDAC progression by inhibiting CD8+ T cell infiltration through upregulating PD-L1 expression via HIF-1α … DOI 10.1016/j.tranon.2024.102261↗
- Xueli Zhang · 1 shared paper, 2025 · strength 0.22
- Xiaomei Yang · 1 shared paper, 2025 · strength 0.22
- Hong‐Fei Yao · 1 shared paper, 2025 · strength 0.21
- Linli Yao · 1 shared paper, 2025 · strength 0.21
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.